Prader Willi/Angelman region RNA 6Genealiases: HBT8 · PAR-6
Q-omics provides the consensus-scored PWAR6 profile across patient tissues and cancer cell-line models. PWAR6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PWAR6 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, PWAR6 RNA expression shows 20,463 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where PWAR6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PWAR6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PWAR6 survival associations across molecular data types. PWAR6 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PWAR6 RNA expression–survival associations across cancer types. High PWAR6 expression shows unfavorable associations in UVM and ACC, but favorable associations in HNSC, LGG, PAAD and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for PWAR6 RNA expression.
This table summarizes PWAR6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PWAR6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PWAR6 shows lower tumor expression in KIRC, BLCA, KIRP, THCA, LUAD and LUSC. The KIRC box plot shows higher PWAR6 RNA expression in normal versus tumor tissue (log2 FC = −1.241, t-test p < 0.001).
This table shows molecular features associated with PWAR6 in patient tissues and cancer cell lines. In patient samples, PWAR6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
